Text Size
Trial record 3 of 48 for:    Open Studies | "Orthostatic Intolerance"
Previous Study | Return to List | Next Study

Genetic Basis of Mitral Valve Prolapse (MVP)

This study is currently recruiting participants.
Verified October 2012 by Massachusetts General Hospital
Sponsor:
Collaborator:
Leducq Foundation
Information provided by (Responsible Party):
Robert A. Levine, MD, Massachusetts General Hospital
ClinicalTrials.gov Identifier:
NCT01719211
First received: October 30, 2012
Last updated: October 31, 2012
Last verified: October 2012
History of Changes
  Purpose

The investigators have successfully identified two novel genetic loci for MVP on chromosomes 11 and 13 and are searching for altered genes in these regions. This requires recruiting large families who may have MVP linked to these or other chromosomes; and obtaining DNA samples from 1,000-1,500 individually affected patients to study the relation between DNA markers throughout the genome and MVP. It is our expectation that the results of this study will lead to the discovery of gene(s) responsible for MVP. This will lead to improved understanding of the disease and, in turn, improved ability to treat and prevent progression in genetically susceptible individuals.


Condition
Mitral Valve Prolapse

Study Type: Observational
Study Design: Time Perspective: Prospective
Official Title: Genetic Basis of Mitral Valve Prolapse

Resource links provided by NLM:

U.S. FDA Resources

Further study details as provided by Massachusetts General Hospital:

Primary Outcome Measures:
  • Discovery of the genetic basis of Mitral Valve Prolapse [ Time Frame: 5 years ] [ Designated as safety issue: No ]
    Genome-wide association


Biospecimen Retention:   Samples With DNA

DNA


Estimated Enrollment: 1500
Study Start Date: January 1999
Estimated Study Completion Date: December 2020
Estimated Primary Completion Date: December 2020 (Final data collection date for primary outcome measure)
Detailed Description:

This is a genome-wide association study.

  Eligibility

Ages Eligible for Study:   18 Years to 80 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

Patients referred for 2D echo for MVP

Criteria

Inclusion Criteria:

  • Mitral valve prolapse

Exclusion Criteria:

  • Other mitral valve diseases
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01719211

Contacts
Contact: Susan Slaugenhaupt, PhD 6176433217 slaugenhaupt@chgr.mgh.harvard.edu
Contact: Robert a levine, MD 6177241995 rlevine@partners.org

Locations
United States, Massachusetts
Mass General Hospital Recruiting
Boston, Massachusetts, United States, 02114
Sponsors and Collaborators
Massachusetts General Hospital
Leducq Foundation
Investigators
Principal Investigator: robert a levine, MD Mass General Hospital
  More Information

No publications provided

Responsible Party: Robert A. Levine, MD, Cardiologist, Massachusetts General Hospital
ClinicalTrials.gov Identifier: NCT01719211     History of Changes
Other Study ID Numbers: 1999-p-007948
Study First Received: October 30, 2012
Last Updated: October 31, 2012
Health Authority: United States: Institutional Review Board

Keywords provided by Massachusetts General Hospital:
MVP, mitral valve

Additional relevant MeSH terms:
Mitral Valve Prolapse
Orthostatic Intolerance
Neurocirculatory Asthenia
Prolapse
Heart Valve Prolapse
Heart Valve Diseases
Heart Diseases
Cardiovascular Diseases
 Anxiety Disorders
Mental Disorders
Primary Dysautonomias
Autonomic Nervous System Diseases
Nervous System Diseases
Neurologic Manifestations
Signs and Symptoms
Pathological Conditions, Anatomical

ClinicalTrials.gov processed this record on May 22, 2013